A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours

British Journal of Cancer

Volumn 104, Issue 11, 2011, Pages 1716-1723

  Borriello, M ^a   Laccetti, P ^a   Terrazzano, G ^a,b   D'Alessio, G ^a   De Lorenzo, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BASILICATA   (Italy)

Author keywords

breast cancer; ErbB2 HER2; immunoRNase; immunotherapy; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; RIBONUCLEASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG DESIGN; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOCONJUGATES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; RIBONUCLEASE, PANCREATIC; RIBONUCLEASES;

EID: 79957607664     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.146     Document Type: Article

References (35)

1. Adams GP, Weiner LM (2005) Monoclonal antibody therapy. Nat Biotechnol 23: 1147-1157
2. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW (1999) Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res 59: 4761-4764 (Pubitemid 29472871)
3. Bartholeyns J, Wang D, Blackburn P, Wilson G, Moore S, Stein WH (1977) Explanation of the observation of pancreatic ribonuclease activity at pH 4.5. Int J Pept Protein Res 10: 172-175 (Pubitemid 8162720)
4. Blank A, Sugiyama RH, Dekker CA (1982) Activity staining of nucleolytic enzymes after sodium dodecyl-sulfate-polyacrylamide gel electrophor-esis: use of aqueous isopropanol to remove detergent from gels. Anal Biochem 120: 267-275
5. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118-129 (Pubitemid 33741887)
6. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R, D'Alessio G (2004a) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64: 4870-4874 (Pubitemid 38924531)
7. De Lorenzo C, D'Alessio G (2008) From immunotoxins to immunoRNase. Curr Pharm Biotechnol 9: 210-214
8. De Lorenzo C, D'Alessio G (2009) Human anti-ErbB2 immunoagents- immunoRNases and compact antibodies. FEBS J 276: 1527-1535
9. De Lorenzo C, Di Malta C, Cal̀ý G, Troise F, Nitsch L, D'Alessio G (2007) Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett 581: 296-300 (Pubitemid 46096473)
10. De Lorenzo C, Nigro A, Piccoli R, D'Alessio G (2002a) A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. FEBS Lett 516: 208-212 (Pubitemid 34311963)
11. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G (2002b) A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8: 1710-1719 (Pubitemid 34633726)
12. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G (2004b) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91: 1200-1204 (Pubitemid 39336263)
13. Di Carlo E, Diodoro MG, Boggio K, Modesti A, Modesti M, Nanni P, Forni G, Musiani P (1999) Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest 79: 1261-1269 (Pubitemid 29489450)
14. Drebrin JA, Link VC, Greene MI (1988) Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2: 387-394
15. Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C (2010) Two novel human anti-ErbB2 immuno-agents are active on trastuzumab-resistant tumours. Br J Cancer 102: 513-519
16. Gong SJ, Jin CJ, Rha SY, Chung HC (2004) Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214: 215-224 (Pubitemid 39207983)
17. Harris M (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292-302 (Pubitemid 38541581)
18. Jørgensen JT (2010) Targeted HER2 treatment in advanced gastric cancer. Oncology 78: 26-33
19. Li J, Zhu Z (2010) Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 31: 1198-1207
20. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dübel S (2008) Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 111: 3830-3837
21. Naddeo M, Vitagliano L, Russo A (2005) Interactions of the cytotoxic RNase A dimers with the cytosolic ribonuclease inhibitor. FEBS Lett 579: 2663-2668 (Pubitemid 40615674)
22. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280 (Pubitemid 43731112)
23. Pastan I, FitzGerald D (1991) Recombinant toxins for cancer treatment. Science 254: 1173-1177 (Pubitemid 21917443)
24. Reiter Y, Pastan I (1998) Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol 16: 513-520 (Pubitemid 28552663)
25. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, De Lorenzo C (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23: 3171-3178
26. Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165: 5133-5142
27. Rybak SM, Newton DL (1999) Natural and engineered cytotoxic ribonucleases: therapeutic potential. Exp Cell Res 253: 325-335 (Pubitemid 30003093)
28. Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES (2001) The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Curr Opin Oncol 13: 168-175
29. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221 (Pubitemid 34177427)
30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182 (Pubitemid 17231334)
31. Stebbing J, Copson E, O'Reilly S (2000) Herceptin (trastuzumab) in advanced breast cancer. Cancer Treat Rev 26: 287-290 (Pubitemid 30604039)
32. Venkiteshwaran A (2009) Tocilizumab. MAbs 1: 432-438
33. Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES (1989) Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A immunoconjugate. Cancer Res 49: 4062-4067 (Pubitemid 19197446)
34. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77: 1-10 (Pubitemid 28029765)
35. Zhang Q, Chen G, Liu X, Qian Q (2007) Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 17: 89-99 (Pubitemid 46279233)